First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis
© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies..
ABSTRACT: SETBP1 mutations are found in various clonal myeloid disorders. However, it is unclear whether they can initiate leukemia, because SETBP1 mutations typically appear as later events during oncogenesis. To answer this question, we generated a mouse model expressing mutated SETBP1 in hematopoietic tissue: this model showed profound alterations in the differentiation program of hematopoietic progenitors and developed a myeloid neoplasm with megakaryocytic dysplasia, splenomegaly, and bone marrow fibrosis, prompting us to investigate SETBP1 mutations in a cohort of 36 triple-negative primary myelofibrosis (TN-PMF) cases. We identified 2 distinct subgroups, one carrying SETBP1 mutations and the other completely devoid of somatic variants. Clinically, a striking difference in disease aggressiveness was noted, with patients with SETBP1 mutation showing a much worse clinical course. In contrast to myelodysplastic/myeloproliferative neoplasms, in which SETBP1 mutations are mostly found as a late clonal event, single-cell clonal hierarchy reconstruction in 3 patients with TN-PMF from our cohort revealed SETBP1 to be a very early event, suggesting that the phenotype of the different SETBP1+ disorders may be shaped by the opposite hierarchy of the same clonal SETBP1 variants.
| Errataetall: |
CommentIn: Blood. 2024 Apr 4;143(14):1323-1324. - PMID 38573606 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:143 |
|---|---|
| Enthalten in: |
Blood - 143(2024), 14 vom: 04. Apr., Seite 1399-1413 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Carrier Proteins |
|---|
| Anmerkungen: |
Date Completed 05.04.2024 Date Revised 05.04.2024 published: Print CommentIn: Blood. 2024 Apr 4;143(14):1323-1324. - PMID 38573606 Citation Status MEDLINE |
|---|
| doi: |
10.1182/blood.2023021349 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366852949 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366852949 | ||
| 003 | DE-627 | ||
| 005 | 20240405233353.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/blood.2023021349 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1366.xml |
| 035 | |a (DE-627)NLM366852949 | ||
| 035 | |a (NLM)38194688 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Crespiatico, Ilaria |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.04.2024 | ||
| 500 | |a Date Revised 05.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Blood. 2024 Apr 4;143(14):1323-1324. - PMID 38573606 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies. | ||
| 520 | |a ABSTRACT: SETBP1 mutations are found in various clonal myeloid disorders. However, it is unclear whether they can initiate leukemia, because SETBP1 mutations typically appear as later events during oncogenesis. To answer this question, we generated a mouse model expressing mutated SETBP1 in hematopoietic tissue: this model showed profound alterations in the differentiation program of hematopoietic progenitors and developed a myeloid neoplasm with megakaryocytic dysplasia, splenomegaly, and bone marrow fibrosis, prompting us to investigate SETBP1 mutations in a cohort of 36 triple-negative primary myelofibrosis (TN-PMF) cases. We identified 2 distinct subgroups, one carrying SETBP1 mutations and the other completely devoid of somatic variants. Clinically, a striking difference in disease aggressiveness was noted, with patients with SETBP1 mutation showing a much worse clinical course. In contrast to myelodysplastic/myeloproliferative neoplasms, in which SETBP1 mutations are mostly found as a late clonal event, single-cell clonal hierarchy reconstruction in 3 patients with TN-PMF from our cohort revealed SETBP1 to be a very early event, suggesting that the phenotype of the different SETBP1+ disorders may be shaped by the opposite hierarchy of the same clonal SETBP1 variants | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a SETBP1 protein, human |2 NLM | |
| 650 | 7 | |a Carrier Proteins |2 NLM | |
| 650 | 7 | |a Nuclear Proteins |2 NLM | |
| 700 | 1 | |a Zaghi, Mattia |e verfasserin |4 aut | |
| 700 | 1 | |a Mastini, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a D'Aliberti, Deborah |e verfasserin |4 aut | |
| 700 | 1 | |a Mauri, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Mercado, Carl Mirko |e verfasserin |4 aut | |
| 700 | 1 | |a Fontana, Diletta |e verfasserin |4 aut | |
| 700 | 1 | |a Spinelli, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Crippa, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Inzoli, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Manghisi, Beatrice |e verfasserin |4 aut | |
| 700 | 1 | |a Civettini, Ivan |e verfasserin |4 aut | |
| 700 | 1 | |a Ramazzotti, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Sangiorgio, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Gengotti, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Brambilla, Virginia |e verfasserin |4 aut | |
| 700 | 1 | |a Aroldi, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Banfi, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Barone, Cristiana |e verfasserin |4 aut | |
| 700 | 1 | |a Orsenigo, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Riera, Ludovica |e verfasserin |4 aut | |
| 700 | 1 | |a Riminucci, Mara |e verfasserin |4 aut | |
| 700 | 1 | |a Corsi, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Breccia, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Morotti, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Cilloni, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Roccaro, Aldo |e verfasserin |4 aut | |
| 700 | 1 | |a Sacco, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Stagno, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Serafini, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Mottadelli, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Cazzaniga, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Pagni, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Chiarle, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Azzoni, Emanuele |e verfasserin |4 aut | |
| 700 | 1 | |a Sessa, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Gambacorti-Passerini, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Elli, Elena Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Mologni, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Piazza, Rocco |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood |d 1946 |g 143(2024), 14 vom: 04. Apr., Seite 1399-1413 |w (DE-627)NLM000014761 |x 1528-0020 |7 nnns |
| 773 | 1 | 8 | |g volume:143 |g year:2024 |g number:14 |g day:04 |g month:04 |g pages:1399-1413 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1182/blood.2023021349 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 143 |j 2024 |e 14 |b 04 |c 04 |h 1399-1413 | ||